194 related articles for article (PubMed ID: 26910509)
1. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
2. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
[TBL] [Abstract][Full Text] [Related]
4. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
5. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
[TBL] [Abstract][Full Text] [Related]
7. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.
Robinson ES; Werth VP
Cytokine; 2015 Jun; 73(2):326-34. PubMed ID: 25767072
[TBL] [Abstract][Full Text] [Related]
8. Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus.
Zahn S; Rehkämper C; Ferring-Schmitt S; Bieber T; Tüting T; Wenzel J
Br J Dermatol; 2011 Nov; 165(5):1118-23. PubMed ID: 21711324
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.
Walker A; Erwig L; Foster K; Nevin K; Wenzel J; Worm M; Williams N; Ratia N; Hoang B; Schneider-Merck T; Gisbert S; Carnarius H; Dickson M
Exp Dermatol; 2021 Nov; 30(11):1686-1692. PubMed ID: 33336508
[TBL] [Abstract][Full Text] [Related]
10. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
Yu C; Chang C; Zhang J
J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
Zhang YP; Wu J; Han YF; Shi ZR; Wang L
Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus.
Zahn S; Rehkämper C; Kümmerer BM; Ferring-Schmidt S; Bieber T; Tüting T; Wenzel J
J Invest Dermatol; 2011 Jan; 131(1):133-40. PubMed ID: 20720564
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus.
Wang D; Drenker M; Eiz-Vesper B; Werfel T; Wittmann M
Arthritis Rheum; 2008 Oct; 58(10):3205-15. PubMed ID: 18821674
[TBL] [Abstract][Full Text] [Related]
15. NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.
Vorwerk G; Zahn S; Bieber T; Wenzel J
Exp Dermatol; 2021 Jun; 30(6):847-852. PubMed ID: 33687107
[TBL] [Abstract][Full Text] [Related]
16. Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.
Issara-Amphorn J; Chancharoenthana W; Visitchanakun P; Leelahavanichkul A
J Innate Immun; 2020; 12(6):461-479. PubMed ID: 32927460
[TBL] [Abstract][Full Text] [Related]
17. The classification and diagnosis of cutaneous lupus erythematosus.
Kuhn A; Landmann A
J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
[TBL] [Abstract][Full Text] [Related]
18. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.
Sarkar MK; Hile GA; Tsoi LC; Xing X; Liu J; Liang Y; Berthier CC; Swindell WR; Patrick MT; Shao S; Tsou PS; Uppala R; Beamer MA; Srivastava A; Bielas SL; Harms PW; Getsios S; Elder JT; Voorhees JJ; Gudjonsson JE; Kahlenberg JM
Ann Rheum Dis; 2018 Nov; 77(11):1653-1664. PubMed ID: 30021804
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
Skiljevic D; Bonaci-Nikolic B; Brasanac D; Nikolic M
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):523-529. PubMed ID: 27557471
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray.
Toberer F; Sykora J; Göttel D; Hartschuh W; Werchau S; Enk A; Joos S; Krammer PH; Kuhn A
Exp Dermatol; 2013 Oct; 22(10):656-9. PubMed ID: 24079735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
